Key result
Inpatient hs-cTn elevation primarily reflects non-thrombotic myocardial injury or type 2 MI rather than type 1 MI.
Why the study?
High-sensitivity cardiac troponin assays have increased detection of myocardial injury in hospitalized patients, but clinical practice has not fully adapted to distinguishing biomarker positivity from MI, leading to reflexive MI labeling, antithrombotic therapy, and low-yield invasive testing.
This narrative review highlights that hs-cTn elevation in hospitalized patients frequently reflects non-thrombotic myocardial injury or type 2 MI, advocating for a probability-driven, mechanism-based diagnostic framework to prevent inappropriate invasive testing and mislabeling.
Answers are grounded in this paper and cite their sources.
Supports mechanism-based troponin interpretation to reduce misdiagnosis and unnecessary angiography; leaves open prospective validation before practice change.
High-sensitivity cardiac troponin (hs-cTn) assays have increased detection of myocardial injury in hospitalized patients, but clinical practice has not fully adapted to the distinction between biomarker positivity and myocardial infarction (MI). In medically complex inpatients, troponin elevation commonly reflects myocardial injury or type 2 MI rather than acute coronary thrombosis. As a result, reflexive labeling as MI can trigger antithrombotic therapy, low-yield invasive testing, and durable diagnostic labels that shape downstream care. This narrative review synthesizes contemporary consensus definitions, guideline statements, and peer-reviewed clinical studies relevant to hs-cTn interpretation in hospitalized and critically ill adults. Emphasis is placed on classification, inpatient diagnostic pitfalls, management patterns, and downstream consequences of misclassification, including common inpatient contexts such as sepsis, perioperative illness, tachyarrhythmias, and chronic kidney disease. Across inpatient cohorts, hs-cTn elevation is frequent, whereas adjudicated type 1 MI represents a minority of abnormal results. Mechanisms of troponin release extend beyond plaque rupture and include inflammatory signaling, membrane permeability changes, apoptosis, and mechanical stretch in overlapping physiologic stressors. Observational studies suggest that diagnostic labeling influences care trajectories, with higher rates of coronary angiography and secondary prevention therapy without clear long-term mortality benefit. In addition, cognitive heuristics, indiscriminate testing, and incomplete clinical context contribute to diagnostic momentum. Accordingly, hs-cTn elevation should be interpreted using a probability-driven, mechanism-based framework that requires ischemic corroboration to diagnose MI, uses serial change to determine acuity rather than mechanism, prioritizes identification and treatment of reversible stressors, and escalates to imaging or invasive evaluation selectively when ischemic suspicion remains high.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) conducted a review in Myocardial injury and myocardial infarction in hospitalized and critically ill patients. High-sensitivity cardiac troponin (hs-cTn) elevation interpretation was evaluated. High-sensitivity cardiac troponin elevation in inpatients commonly reflects non-thrombotic myocardial injury or type 2 MI rather than type 1 MI, requiring a mechanism-based diagnostic framework.
Synapse has enriched 10 related papers. Consider them for comparative context: